



## **Ascendant Capital Markets LLC serves as Financial Advisor on \$70,000,000 Initial Public Offering (IPO) for Lucid Diagnostics, Inc.**

JUPITER, Florida – October 20, 2021 -- Ascendant Capital Markets LLC (“Ascendant”) announced today the closing of a \$70,000,000 Initial Public Offering (IPO) for Lucid Diagnostics, Inc. (Nasdaq: LUCD) of New York, New York.

Ascendant served as Financial Advisor on the transaction.

Lucid intends to expand sales infrastructure, to optimize the pilot launch of its Lucid Test Centers and the EsoGuard Telemedicine Program, to complete ongoing clinical trials, and to expand manufacturing and laboratory capacity.

### **About Lucid Diagnostics, Inc.**

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing. For more information, please visit [www.luciddx.com](http://www.luciddx.com)

### **About Ascendant Capital Markets LLC**

Ascendant Capital Markets, LLC, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendant has led or participated in over \$1 billion in financing transactions, and the members of Ascendant’s Investment Banking Team have completed over 300 M&A transactions.

Ascendant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit [www.ascendant.com](http://www.ascendant.com) or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 561.427.1727 or [bwilhite@ascendant.com](mailto:bwilhite@ascendant.com)

*This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.*

---

#### **ASCENDANT CAPITAL MARKETS, LLC**

110 Front Street, Suite 300, Jupiter, Florida 33477

561.427.7788 | [www.ascendant.com](http://www.ascendant.com)

Member FINRA & SIPC